JPMorgan raises target for AbbVie stock to USD 300

Published on 10/19/2026 at 09:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 10.20 percent to USD 16.99 billion in the second quarter. AbbVie stock costs EUR 254.35 on October 19, 2026, 0.49 percent above Xetra close.

Growth, valuation and upcoming dates

The target rose from USD 285.00 to USD 300.00 on October 8, 2026.
Second-quarter revenue reached USD 16.99 billion, up 10.20 percent year over year.
AbbVie stock trades at EUR 254.35 at 9:22 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.49 percent above the Xetra close of October 16, 2026.
Third-quarter results are scheduled for October 30, 2026.
Market capitalization stood at USD 504.4 billion as of October 16, 2026.

Extreme Makroaufnahme irisierender pharmazeutischer Kristallstrukturen unter polarisiertem Mikroskoplicht — AbbVie Inc. US00287Y1091 Makrofotografie irisierender kristalliner Molekülstrukturen unter polarisiertem Mikroskoplicht Biopharma Forschung, Illustration mit AI erstellt.

AbbVie Inc. (ISIN US00287Y1091) was trading at EUR 254.35 at Lang & Schwarz on October 19, 2026, at 9:22 a.m. CEST, up 0.49 percent versus the Xetra close of October 16, 2026 at EUR 253.10. The move follows JPMorgan's October 8 target increase from USD 285.00 to USD 300.00, as MarketBeat reported on October 9, 2026.

Second-quarter growth sets the test

AbbVie reported USD 16.99 billion in second-quarter revenue, a 10.20 percent increase from the same period a year earlier. Adjusted earnings per share reached USD 3.65, compared with USD 2.97 in the prior-year quarter, according to MarketBeat.

The operating picture is mixed beneath the headline growth. Humira revenue fell 35.90 percent to USD 756.00 million, while newer medicines helped lift total sales. The comparison shows why the pipeline, rather than the legacy franchise alone, is central to the valuation.

What does the target change mean?

The target increase gives the stock a higher hurdle before the next results. The USD 300.00 target is USD 15.00 above the previous target, while the company is guiding for third-quarter adjusted earnings per share of USD 3.84 to USD 3.88, figures reported by MarketBeat.

Three dates trace the story

On April 29, 2026, AbbVie reported first-quarter revenue of USD 15.00 billion, according to MarketBeat. On July 31, 2026, second-quarter revenue reached USD 16.99 billion, up 10.20 percent year over year, before JPMorgan raised its target on October 8, 2026.

The next two dated catalysts are the third-quarter results on October 30, 2026, before the market opens, and the USD 1.73 per-share dividend payment scheduled for November 16, 2026. The earnings date comes from AbbVie, while the payment date was reported by MarketBeat.

Valuation remains near the yearly high

AbbVie had a market capitalization of USD 504.4 billion and a 52-week range of USD 190.75 to USD 291.40 as of October 16, 2026. The current euro quote is therefore positioned near the upper end of the documented annual range when viewed alongside the primary-market context.

The stock was trading at EUR 254.35 at Lang & Schwarz on October 19, 2026, at 9:22 a.m. CEST, 0.49 percent above the Xetra close of October 16, 2026 at EUR 253.10. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.